| content | |||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
JWH-171
|
|
| Systematic (IUPAC) name | |
| 1-([(1E)-3-pentylinden-1-ylidine]methyl)naphthalene | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C25H24 |
| Mol. mass | 324.457 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Legal |
| Routes | ? |
JWH-171 is an analgesic drug which acts as a cannabinoid receptor agonist. Its binding affinity at the CB1 receptor is only 51nM, making it slightly less potent than THC itself,[1] however JWH-171 is particularly notable in that it is a hydrocarbon containing no heteroatoms. This demonstrates that reasonably high-affinity cannabinoid binding and agonist effects can be produced by compounds with no hydrogen bonding capacity at all, relying merely on Van der Waals interactions to bind to the receptor.[2]
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
References
- ^ Huffman JW, Padgett LW. Recent Developments in the Medicinal Chemistry of Cannabimimetic Indoles, Pyrroles and Indenes. Current Medicinal Chemistry, 2005; 12: 1395-1411.
- ^ Roger Pertwee. Cannabinoids. Handbook of Experimental Pharmacology Volume 168, p 269. Springer. ISBN 3-540-22565-X
